{"success":true,"data":{"pressRelease":{"id":"161934","rtpr_id":"nGNX3Fz19f-20261006","ticker":"INMB","exchange":"NASDAQ","all_tickers":["INMB"],"title":"INmune Bio to Attend the 2026 Maxim Growth Summit","author":"Globe Newswire","published_at":"2026-10-06T13:00:02.315Z","article_body":"BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:\nINMB) (the “Company”), a late-stage biotechnology company focused on\ninflammation and immunology, is excited to announce its participation in the\nupcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at\nThe Hard Rock Hotel NYC. This prestigious event brings together industry\nleaders, innovators, and premier institutions to explore the latest trends and\nadvancements across several industries.\n\nINmune Bio will be meeting with institutional investors in one-on-one sessions\nand engaging with senior Maxim research analysts throughout the event. Company\nCEO David Moss will also be presenting on an Immunology & Inflammation\nTherapies Panel on Thursday Oct. 14(th) at 10:30am.\n\nKeynote speakers include Marcus Lemonis (co-owner of Camping World and\nexecutive chairman of Neighborhood Intelligence) and Eric Adams (former mayor\nof New York City). The conference will also feature roundtable discussions\nwith CEOs from small- and mid-cap companies, moderated by Maxim research\nanalysts. Roundtable discussions will cover a range of sectors, including\nbiotechnology, artificial intelligence, quantum technology, digital assets,\nenergy and mining, drones, and more.\n\nThis year, portions of the event will also be streamed online at\nhttps://digital.maximgrp.com/.\n\nFor more information and a complete agenda of the Maxim Growth Summit, please\nvisit www.maximgrp.com/2026-growth-summit.\n\nAbout Maxim Group LLC\n\nMaxim Group LLC is a full-service investment banking, securities and wealth\nmanagement firm headquartered in New York. The independent and employee-owned\nfirm provides a full array of financial services including investment banking;\nprivate wealth management; and global institutional equity, fixed-income and\nderivatives sales & trading, equity research and prime brokerage services.\nMaxim Group LLC is a registered broker-dealer with the U.S. Securities and\nExchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB)\nand is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group\nLLC, visit maximgrp.com.\n\nAbout INmune Bio Inc.\n\nINmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology\ncompany focused on developing treatments that target the innate immune system\nto fight disease. The Company’s clinical-development strategy centers on\nadvanced precision medicine, matching drug mechanisms directly to patient\nbiology to optimize clinical outcomes.\n\nINmune Bio is actively advancing two late-stage product platforms toward\nregistrational milestones:\n* CORDStrom™: A proprietary, pooled, allogeneic, human umbilical\ncord-derived mesenchymal stromal cell platform engineered to address the\nhistorical clinical challenges of donor variability and manufacturing\ninconsistency. Following successful clinical readouts in RDEB, the platform is\ntransitioning to regulatory filing phases, with an MAA planned for the UK MHRA\nin 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License\nApplication (BLA) submission.\n* XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform\ndesigned to selectively neutralize soluble TNF (sTNF) and reduce\nneuroinflammation without compromising protective immune function. Backed by\nrecently granted FDA Fast Track designation and successful regulatory\nalignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an\nintegrated Phase 2b/3 seamless adaptive registrational program in\nneuroinflammation-enriched early Alzheimer’s disease. \nTo learn more about INmune Bio’s pipeline and its approach to harnessing the\ninnate immune system, please visit www.inmunebio.com.\n\nForward Looking Statements\n\nThe Company’s product candidates remain in clinical development stage and\nthere is no assurance that any specific outcome will be achieved. Any\nstatements contained in this press release related to the development or\ncommercialization of product candidates and other business and financial\nmatters, including without limitation, trial results and data, including\n Ebstrocel™, XPro™ and INKmune™ trial results, timing of key\nmilestones, future plans or expectations, and the prospects for receiving\nregulatory approval or commercializing or selling any product or drug\ncandidates, may constitute forward-looking statements as that term is defined\nin the Private Securities Litigation Reform Act of 1995. Any forward-looking\nstatements contained herein are based on current expectations but are subject\nto several risks and uncertainties. Actual results and the timing of certain\nevents and circumstances may differ materially from those described by the\nforward-looking statements because of these risks and uncertainties.\nCORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either\nfinished clinical trials, are still in clinical trials or are preparing to\nstart clinical trials and have not been approved by the US Food and Drug\nAdministration (FDA), the UK MHRA or any regulatory body and there cannot be\nany assurance that they will be approved by the FDA, the UK MHRA or any\nregulatory body or that any specific results will be achieved. The factors\nthat could cause actual future results to differ materially from current\nexpectations include, but are not limited to, risks and uncertainties relating\nto the Company’s ability to produce more drug for clinical trials; the\navailability of substantial additional funding for the Company to continue its\noperations and to conduct research and development, clinical studies and\nfuture product commercialization; and the Company’s business, research,\nproduct development, regulatory approval, marketing and distribution plans and\nstrategies. These and other factors are identified and described in more\ndetail in the Company’s filings with the Securities and Exchange Commission,\nincluding the Company’s Annual Report on Form 10-K, the Company’s\nQuarterly Reports on Form 10-Q and the Company’s Current Reports on Form\n8-K. The Company assumes no obligation to update any forward-looking\nstatements to reflect any event or circumstance that may arise after the date\nof this release.\n\nINmune Bio Contacts: \nDavid Moss \nChief Executive Officer \n(561) 710-0512 \ninfo@inmunebio.com\n\nDaniel Carlson \nHead of Investor Relations \n(415) 509-4590 \ndcarlson@inmunebio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/64035ec0-9fc2-414d-a693-27f1b1e90a31)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3Fz19f-20261006","title":"INmune Bio to Attend the 2026 Maxim Growth Summit","author":"Globe Newswire","ticker":"INMB","created":"2026-10-06T13:00:02.315Z","tickers":["INMB"],"exchange":"NASDAQ","article_body":"BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:\nINMB) (the “Company”), a late-stage biotechnology company focused on\ninflammation and immunology, is excited to announce its participation in the\nupcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at\nThe Hard Rock Hotel NYC. This prestigious event brings together industry\nleaders, innovators, and premier institutions to explore the latest trends and\nadvancements across several industries.\n\nINmune Bio will be meeting with institutional investors in one-on-one sessions\nand engaging with senior Maxim research analysts throughout the event. Company\nCEO David Moss will also be presenting on an Immunology & Inflammation\nTherapies Panel on Thursday Oct. 14(th) at 10:30am.\n\nKeynote speakers include Marcus Lemonis (co-owner of Camping World and\nexecutive chairman of Neighborhood Intelligence) and Eric Adams (former mayor\nof New York City). The conference will also feature roundtable discussions\nwith CEOs from small- and mid-cap companies, moderated by Maxim research\nanalysts. Roundtable discussions will cover a range of sectors, including\nbiotechnology, artificial intelligence, quantum technology, digital assets,\nenergy and mining, drones, and more.\n\nThis year, portions of the event will also be streamed online at\nhttps://digital.maximgrp.com/.\n\nFor more information and a complete agenda of the Maxim Growth Summit, please\nvisit www.maximgrp.com/2026-growth-summit.\n\nAbout Maxim Group LLC\n\nMaxim Group LLC is a full-service investment banking, securities and wealth\nmanagement firm headquartered in New York. The independent and employee-owned\nfirm provides a full array of financial services including investment banking;\nprivate wealth management; and global institutional equity, fixed-income and\nderivatives sales & trading, equity research and prime brokerage services.\nMaxim Group LLC is a registered broker-dealer with the U.S. Securities and\nExchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB)\nand is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group\nLLC, visit maximgrp.com.\n\nAbout INmune Bio Inc.\n\nINmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology\ncompany focused on developing treatments that target the innate immune system\nto fight disease. The Company’s clinical-development strategy centers on\nadvanced precision medicine, matching drug mechanisms directly to patient\nbiology to optimize clinical outcomes.\n\nINmune Bio is actively advancing two late-stage product platforms toward\nregistrational milestones:\n* CORDStrom™: A proprietary, pooled, allogeneic, human umbilical\ncord-derived mesenchymal stromal cell platform engineered to address the\nhistorical clinical challenges of donor variability and manufacturing\ninconsistency. Following successful clinical readouts in RDEB, the platform is\ntransitioning to regulatory filing phases, with an MAA planned for the UK MHRA\nin 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License\nApplication (BLA) submission.\n* XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform\ndesigned to selectively neutralize soluble TNF (sTNF) and reduce\nneuroinflammation without compromising protective immune function. Backed by\nrecently granted FDA Fast Track designation and successful regulatory\nalignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an\nintegrated Phase 2b/3 seamless adaptive registrational program in\nneuroinflammation-enriched early Alzheimer’s disease. \nTo learn more about INmune Bio’s pipeline and its approach to harnessing the\ninnate immune system, please visit www.inmunebio.com.\n\nForward Looking Statements\n\nThe Company’s product candidates remain in clinical development stage and\nthere is no assurance that any specific outcome will be achieved. Any\nstatements contained in this press release related to the development or\ncommercialization of product candidates and other business and financial\nmatters, including without limitation, trial results and data, including\n Ebstrocel™, XPro™ and INKmune™ trial results, timing of key\nmilestones, future plans or expectations, and the prospects for receiving\nregulatory approval or commercializing or selling any product or drug\ncandidates, may constitute forward-looking statements as that term is defined\nin the Private Securities Litigation Reform Act of 1995. Any forward-looking\nstatements contained herein are based on current expectations but are subject\nto several risks and uncertainties. Actual results and the timing of certain\nevents and circumstances may differ materially from those described by the\nforward-looking statements because of these risks and uncertainties.\nCORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either\nfinished clinical trials, are still in clinical trials or are preparing to\nstart clinical trials and have not been approved by the US Food and Drug\nAdministration (FDA), the UK MHRA or any regulatory body and there cannot be\nany assurance that they will be approved by the FDA, the UK MHRA or any\nregulatory body or that any specific results will be achieved. The factors\nthat could cause actual future results to differ materially from current\nexpectations include, but are not limited to, risks and uncertainties relating\nto the Company’s ability to produce more drug for clinical trials; the\navailability of substantial additional funding for the Company to continue its\noperations and to conduct research and development, clinical studies and\nfuture product commercialization; and the Company’s business, research,\nproduct development, regulatory approval, marketing and distribution plans and\nstrategies. These and other factors are identified and described in more\ndetail in the Company’s filings with the Securities and Exchange Commission,\nincluding the Company’s Annual Report on Form 10-K, the Company’s\nQuarterly Reports on Form 10-Q and the Company’s Current Reports on Form\n8-K. The Company assumes no obligation to update any forward-looking\nstatements to reflect any event or circumstance that may arise after the date\nof this release.\n\nINmune Bio Contacts: \nDavid Moss \nChief Executive Officer \n(561) 710-0512 \ninfo@inmunebio.com\n\nDaniel Carlson \nHead of Investor Relations \n(415) 509-4590 \ndcarlson@inmunebio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/64035ec0-9fc2-414d-a693-27f1b1e90a31)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T13:00:02.724350524Z","server_sent_at_ms":1791291602724},"received_at":"2026-10-06T13:00:02.775Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}